

# Sid E O'bryant

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7459698/publications.pdf>

Version: 2024-02-01

179  
papers

10,879  
citations

53789

45  
h-index

36025

97  
g-index

188  
all docs

188  
docs citations

188  
times ranked

14386  
citing authors

#	ARTICLE	IF	CITATIONS
1	Medical comorbidities and ethnicity impact plasma Alzheimer's disease biomarkers: Important considerations for clinical trials and practice. <i>Alzheimer's and Dementia</i> , 2023, 19, 36-43.	0.8	30
2	A blood screening tool for detecting mild cognitive impairment and Alzheimer's disease among community-dwelling Mexican Americans and non-Hispanic Whites: A method for increasing representation of diverse populations in clinical research. <i>Alzheimer's and Dementia</i> , 2022, 18, 77-87.	0.8	21
3	Characterizing plasma NFL in a community-dwelling multi-ethnic cohort: Results from the HABLE study. <i>Alzheimer's and Dementia</i> , 2022, 18, 240-250.	0.8	39
4	Analysis of a precision medicine approach to treating Parkinson's disease: Analysis of the DATATOP study. <i>Parkinsonism and Related Disorders</i> , 2022, 94, 15-21.	2.2	3
5	Neurodegeneration from the AT(N) framework is different among Mexican Americans compared to non-Hispanic Whites: A Health & Aging Brain among Latino Elders (HABLE) Study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12267.	2.4	18
6	Subjective cognitive complaints and cardiovascular risk factors in older Mexican Americans: A cross-sectional study.. <i>Cerebral Circulation - Cognition and Behavior</i> , 2022, 3, 100126.	0.9	1
7	Vascular risk profile and white matter hyperintensity volume among Mexican Americans and non-Hispanic Whites: The HABLE study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12263.	2.4	2
8	Blood biomarkers for cognitive decline and clinical progression in a Mexican American cohort. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12298.	2.4	6
9	Probing the proteome to explore potential correlates of increased Alzheimer's-related cerebrovascular disease in adults with Down syndrome. <i>Alzheimer's and Dementia</i> , 2022, 18, 1744-1753.	0.8	4
10	Metabolic Factors Are Related to Brain Amyloid Among Mexican Americans: A HABS-HD Study. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 1745-1750.	2.6	5
11	Addressing the disparities in dementia risk, early detection and care in Latino populations: Highlights from the second Latinos & Alzheimer's Symposium. <i>Alzheimer's and Dementia</i> , 2022, 18, 1677-1686.	0.8	16
12	Proteomic Profiles of Neurodegeneration Among Mexican Americans and Non-Hispanic Whites in the HABS-HD Study. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 1243-1254.	2.6	6
13	Cardiovascular Risk Factors, Cognitive Dysfunction, and Mild Cognitive Impairment. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2021, 10, 154-162.	1.3	6
14	Plasma Total-Tau and Neurofilament Light Chain as Diagnostic Biomarkers of Alzheimer's Disease Dementia and Mild Cognitive Impairment in Adults with Down Syndrome. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 671-681.	2.6	23
15	Recursive Support Vector Machine Biomarker Selection for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 1691-1700.	2.6	26
16	Relationship of Neurofilament Light (NFL) and Cognitive Performance in a Sample of Mexican Americans with Normal Cognition, Mild Cognitive Impairment and Dementia. <i>Current Alzheimer Research</i> , 2021, 17, 1214-1220.	1.4	9
17	A Precision Medicine Approach to Treating Alzheimer's Disease Using Rosiglitazone Therapy: A Biomarker Analysis of the REFLECT Trials. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 557-568.	2.6	13
18	Polypharmacy and Cognition Function Among Rural Adults. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 607-619.	2.6	7

#	ARTICLE	IF	CITATIONS
19	Acute Regression in Down Syndrome. Brain Sciences, 2021, 11, 1109.	2.3	3
20	Using Fractional Anisotropy Imaging to Detect Mild Cognitive Impairment and Alzheimer's Disease among Mexican Americans and Non-Hispanic Whites: A HABLE Study. Dementia and Geriatric Cognitive Disorders, 2021, 50, 266-273.	1.5	7
21	The Health & Aging Brain among Latino Elders (HABLE) study methods and participant characteristics. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12202.	2.4	36
22	MRI biomarkers of small vessel disease and cognition: A cross-sectional study of a cognitively normal Mexican American cohort. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12236.	2.4	2
23	Plasma Total Tau and Neurobehavioral Symptoms of Cognitive Decline in Cognitively Normal Older Adults. Frontiers in Psychology, 2021, 12, 774049.	2.1	4
24	Accelerating Hyperparameter Tuning in Machine Learning for Alzheimer's Disease With High Performance Computing. Frontiers in Artificial Intelligence, 2021, 4, 798962.	3.4	4
25	Characterization of the Meal-Stimulated Incretin Response and Relationship With Structural Brain Outcomes in Aging and Alzheimer's Disease. Frontiers in Neuroscience, 2020, 14, 608862.	2.8	2
26	Proteomic profiles of prevalent mild cognitive impairment and Alzheimer's disease among adults with Down syndrome. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12023.	2.4	9
27	Human plasma biomarker responses to inhalational general anaesthesia without surgery. British Journal of Anaesthesia, 2020, 125, 282-290.	3.4	27
28	Cognition and the Predictive Utility of Three Risk Scores in an Ethnically Diverse Sample. Journal of Alzheimer's Disease, 2020, 75, 1049-1059.	2.6	6
29	Proteomic profiles of incident mild cognitive impairment and Alzheimer's disease among adults with Down syndrome. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12033.	2.4	4
30	Combining Select Blood-Based Biomarkers with Neuropsychological Assessment to Detect Mild Cognitive Impairment among Mexican Americans. Journal of Alzheimer's Disease, 2020, 75, 739-750.	2.6	3
31	ApoE Genotype-Dependent Response to Antioxidant and Exercise Interventions on Brain Function. Antioxidants, 2020, 9, 553.	5.1	4
32	Proteomic profiles for Alzheimer's disease and mild cognitive impairment among adults with Down syndrome spanning serum and plasma: An Alzheimer's Biomarker Consortium's Down Syndrome (ABC-DS) study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12039.	2.4	13
33	Blood-based biomarkers for Down syndrome and Alzheimer's disease: A systematic review. Developmental Neurobiology, 2019, 79, 699-710.	3.0	16
34	Genome-Wide Methylation of Mild Cognitive Impairment in Mexican Americans Highlights Genes Involved in Synaptic Transport, Alzheimer's Disease-Precursor Phenotypes, and Metabolic Morbidities. Journal of Alzheimer's Disease, 2019, 72, 733-749.	2.6	21
35	Assessing Neuronal and Astrocyte Derived Exosomes From Individuals With Mild Traumatic Brain Injury for Markers of Neurodegeneration and Cytotoxic Activity. Frontiers in Neuroscience, 2019, 13, 1005.	2.8	76
36	Blood Biomarkers for Use in Alzheimer Disease—Moving From “What” to “How?” JAMA Neurology, 2019, 76, 1009.	9.0	15

#	ARTICLE	IF	CITATIONS
37	Potential two-step proteomic signature for Parkinson's disease: Pilot analysis in the Harvard Biomarkers Study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 374-382.	2.4	20
38	Inflammatory Biomarkers, Depressive Symptoms and Falls Among the elderly in Panama. <i>Current Aging Science</i> , 2019, 11, 236-241.	1.2	11
39	A proteomic signature for dementia with Lewy bodies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 270-276.	2.4	18
40	Vascular Depression and Cognition in Mexican Americans. <i>Dementia and Geriatric Cognitive Disorders</i> , 2019, 47, 68-78.	1.5	8
41	Circulating mitochondrial DNA: New indices of type 2 diabetes-related cognitive impairment in Mexican Americans. <i>PLoS ONE</i> , 2019, 14, e0213527.	2.5	45
42	The relationship of CRP and cognition in cognitively normal older Mexican Americans. <i>Medicine (United States)</i> , 2019, 98, e15605.	1.0	23
43	Blood-based protein predictors of dementia severity as measured by $\tau$ : Replication across biofluids and cohorts. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 763-774.	2.4	2
44	Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need. <i>Alzheimer's and Dementia</i> , 2019, 15, 292-312.	0.8	310
45	Levels of $\tau$ -2 Macroglobulin in cognitively normal Mexican- Americans with Subjective Cognitive Decline: A HABLE Study. <i>Current Neurobiology</i> , 2019, 10, 22-25.	1.0	2
46	Characteristics of Cognitively Normal Mexican-Americans with Cognitive Complaints. <i>Journal of Alzheimer's Disease</i> , 2018, 61, 1485-1492.	2.6	8
47	Odorant Item Specific Olfactory Identification Deficit May Differentiate Alzheimer Disease From Aging. <i>American Journal of Geriatric Psychiatry</i> , 2018, 26, 835-846.	1.2	26
48	Texas Mexican American adult normative studies: Normative data for the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). <i>Developmental Neuropsychology</i> , 2018, 43, 27-35.	1.4	12
49	Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies—Gains from AIBL and DIAN Cohort Studies. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 965-992.	2.6	96
50	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 244-328.	2.6	215
51	Texas Mexican American adult normative studies: Normative data for commonly used clinical neuropsychological measures for English- and Spanish-speakers. <i>Developmental Neuropsychology</i> , 2018, 43, 1-26.	1.4	52
52	F501: PROTEOMIC BIOMARKERS FOR DETECTING AND PREDICTING AD RISK AMONG ADULTS WITH DOWN SYNDROME. <i>Alzheimer's and Dementia</i> , 2018, 14, P1624.	0.8	3
53	Current state of Alzheimer's fluid biomarkers. <i>Acta Neuropathologica</i> , 2018, 136, 821-853.	7.7	370
54	Factor structure and measurement invariance of a neuropsychological test battery designed for assessment of cognitive functioning in older Mexican Americans. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 536-544.	2.4	3

#	ARTICLE	IF	CITATIONS
55	Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. <i>Nature Reviews Neurology</i> , 2018, 14, 639-652.	10.1	434
56	A Precision Medicine Model for Targeted NSAID Therapy in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 97-104.	2.6	36
57	The Link between Potassium and Mild Cognitive Impairment in Mexican-Americans. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2018, 8, 151-157.	1.3	16
58	Blood-Based Biomarker Screening with Agnostic Biological Definitions for an Accurate Diagnosis Within the Dimensional Spectrum of Neurodegenerative Diseases. <i>Methods in Molecular Biology</i> , 2018, 1750, 139-155.	0.9	12
59	Transethnic genome-wide scan identifies novel Alzheimer's disease loci. <i>Alzheimer's and Dementia</i> , 2017, 13, 727-738.	0.8	166
60	Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 60-72.	2.4	29
61	Evolving Relevance of Neuroproteomics in Alzheimer's Disease. <i>Methods in Molecular Biology</i> , 2017, 1598, 101-115.	0.9	14
62	A blood-based biomarker panel indicates IL-10 and IL-12/23p40 are jointly associated as predictors of $\beta$ -amyloid load in an AD cohort. <i>Scientific Reports</i> , 2017, 7, 14057.	3.3	22
63	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. <i>Nature Genetics</i> , 2017, 49, 1373-1384.	21.4	783
64	Depression, inflammation, and memory loss among Mexican Americans: analysis of the HABLE cohort. <i>International Psychogeriatrics</i> , 2017, 29, 1693-1699.	1.0	15
65	Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. <i>Alzheimer's and Dementia</i> , 2017, 13, 45-58.	0.8	227
66	[FTS5-02]: HEALTH DISPARITIES IN ALZHEIMER'S DISEASE AMONG MEXICAN AMERICANS. <i>Alzheimer's and Dementia</i> , 2017, 13, P1450.	0.8	0
67	Water T2 as an early, global and practical biomarker for metabolic syndrome: an observational cross-sectional study. <i>Journal of Translational Medicine</i> , 2017, 15, 258.	4.4	22
68	A Depressive Endophenotype for Predicting Cognitive Decline among Mexican American Adults and Elders. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 201-206.	2.6	8
69	Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 3, 27-34.	2.4	44
70	Assessment of the genetic variance of late-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016, 41, 200.e13-200.e20.	3.1	174
71	Introduction to special issue on Advances in blood-based biomarkers of Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 3, 110-112.	2.4	11
72	IL-7 and Depression: The importance of gender and blood fraction. <i>Behavioural Brain Research</i> , 2016, 315, 147-149.	2.2	7

#	ARTICLE	IF	CITATIONS
73	A blood screening test for Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 3, 83-90.	2.4	54
74	Characterization of Alzheimer's Disease and Mild Cognitive Impairment in Older Adults in Panama. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 897-901.	2.6	7
75	Serum-based protein profiles of Alzheimer's disease and mild cognitive impairment in elderly Hispanics. <i>Neurodegenerative Disease Management</i> , 2016, 6, 203-213.	2.2	23
76	An Empirical Comparison of Competing Factor Structures for the Repeatable Battery for the Assessment of Neuropsychological Status: A Project FRONTIER Study. <i>Archives of Clinical Neuropsychology</i> , 2016, 31, 88-96.	0.5	10
77	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <i>Alzheimer's and Dementia</i> , 2016, 12, 292-323.	0.8	1,318
78	Comorbid Depression and Diabetes as a Risk for Mild Cognitive Impairment and Alzheimer's Disease in Elderly Mexican-Americans. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 129-136.	2.6	42
79	Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2015, 48, S171-S191.	2.6	34
80	Biomarkers in Sporadic and Familial Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 291-317.	2.6	75
81	Molecular Markers of Amnesic Mild Cognitive Impairment among Mexican Americans. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 221-228.	2.6	15
82	A depressive endophenotype of poorer cognition among cognitively healthy community-dwelling adults: results from the Western Australia memory study. <i>International Journal of Geriatric Psychiatry</i> , 2015, 30, 881-886.	2.7	9
83	Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research. <i>Alzheimer's and Dementia</i> , 2015, 11, 549-560.	0.8	205
84	Association Between Cognitive Impairment and Chronic Kidney Disease in Mexican Americans. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 2023-2028.	2.6	23
85	S5-01-02: Blood biomarker assays. , 2015, 11, P302-P302.		0
86	An item response theory analysis of the Executive Interview and development of the EXIT8: A Project FRONTIER Study. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2015, 37, 229-242.	1.3	8
87	Total testosterone and neuropsychiatric symptoms in elderly men with Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 24.	6.2	8
88	Molecular markers of neuropsychological functioning and Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 61-66.	2.4	7
89	Innovative diagnostic tools for early detection of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 561-578.	0.8	213
90	Can Genetic Analysis of Putative Blood Alzheimer's Disease Biomarkers Lead to Identification of Susceptibility Loci?. <i>PLoS ONE</i> , 2015, 10, e0142360.	2.5	13

#	ARTICLE	IF	CITATIONS
91	Oxidative Stress, Testosterone, and Cognition among Caucasian and Mexican-American Men with and without Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 563-573.	2.6	40
92	The Link between Sleep Disturbance and Depression among Mexican Americans: A Project FRONTIER Study. <i>Journal of Clinical Sleep Medicine</i> , 2014, 10, 427-431.	2.6	9
93	Executive Functioning and the Metabolic Syndrome: A Project FRONTIER Study. <i>Archives of Clinical Neuropsychology</i> , 2014, 29, 47-53.	0.5	28
94	Arsenic exposure, AS3MT polymorphism, and neuropsychological functioning among rural dwelling adults and elders: a cross-sectional study. <i>Environmental Health</i> , 2014, 13, 15.	4.0	23
95	Molecular Neuropsychology: Creation of Test-Specific Blood Biomarker Algorithms. <i>Dementia and Geriatric Cognitive Disorders</i> , 2014, 37, 45-57.	1.5	13
96	Total Cholesterol and Neuropsychiatric Symptoms in Alzheimer's Disease: The Impact of Total Cholesterol Level and Gender. <i>Dementia and Geriatric Cognitive Disorders</i> , 2014, 38, 300-309.	1.5	11
97	The future of blood-based biomarkers for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 115-131.	0.8	250
98	Comparison of the accuracy of kriging and IDW interpolations in estimating groundwater arsenic concentrations in Texas. <i>Environmental Research</i> , 2014, 130, 59-69.	7.5	198
99	The Hachinski Ischemic Scale and cognition: the influence of ethnicity. <i>Age and Ageing</i> , 2014, 43, 364-369.	1.6	17
100	Regional specific groundwater arsenic levels and neuropsychological functioning: a cross-sectional study. <i>International Journal of Environmental Health Research</i> , 2014, 24, 546-557.	2.7	18
101	Developing novel blood-based biomarkers for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 109-114.	0.8	138
102	Combining Select Neuropsychological Assessment with Blood-Based Biomarkers to Detect Mild Alzheimer's Disease: A Molecular Neuropsychology Approach. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 635-640.	2.6	13
103	Validation of a Serum Screen for Alzheimer's Disease Across Assay Platforms, Species, and Tissues. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 1325-1335.	2.6	73
104	The Impact of APOE Status on Relationship of Biomarkers of Vascular Risk and Systemic Inflammation to Neuropsychiatric Symptoms in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 887-896.	2.6	15
105	O4-11-03: A PROINFLAMMATORY ENDOPHENOTYPE PREDICTS TREATMENT RESPONSE IN A MULTICENTER TRIAL OF NSAIDS IN AD. , 2014, 10, P273-P274.		3
106	P3-086: APOE4 GENOTYPE IMPACTS ACCURACY OF BLOOD ALGORITHM FOR DISTINGUISHING MCI FROM AD. , 2014, 10, P659-P660.		0
107	Cognitive differences among depressed and non-depressed MCI participants: a project FRONTIER study. <i>International Journal of Geriatric Psychiatry</i> , 2013, 28, 377-382.	2.7	35
108	The impact of GPX1 on the association of groundwater selenium and depression: a project FRONTIER study. <i>BMC Psychiatry</i> , 2013, 13, 7.	2.6	32

#	ARTICLE	IF	CITATIONS
109	Androgen receptor gene and sex-specific Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013, 34, 2077.e19-2077.e20.	3.1	13
110	Risk factors for mild cognitive impairment among Mexican Americans. <i>Alzheimer's and Dementia</i> , 2013, 9, 622.	0.8	79
111	A brief Spanish-English equivalent version of the Boston Naming Test: A Project FRONTIER Study. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2013, 35, 835-845.	1.3	12
112	Biomarkers of Vascular Risk, Systemic Inflammation, and Microvascular Pathology and Neuropsychiatric Symptoms in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 35, 363-371.	2.6	73
113	Executive Functioning as a Mediator of the Relationship Between Premorbid Verbal Intelligence and Health Risk Behaviors in a Rural-Dwelling Cohort: A Project FRONTIER Study. <i>Archives of Clinical Neuropsychology</i> , 2013, 28, 169-179.	0.5	5
114	Normative Performance on the Brief Smell Identification Test (BSIT) in a Multi-Ethnic Bilingual Cohort: A Project FRONTIER Study. <i>Clinical Neuropsychologist</i> , 2013, 27, 946-961.	2.3	52
115	Biomarkers of Alzheimer's Disease Among Mexican Americans. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 841-849.	2.6	69
116	The Link Between C-Reactive Protein and Alzheimer's Disease Among Mexican Americans. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 701-706.	2.6	45
117	A Depressive Endophenotype of Mild Cognitive Impairment and Alzheimer's Disease. <i>PLoS ONE</i> , 2013, 8, e68848.	2.5	22
118	Diagnostic Accuracy of the MMSE in Detecting Probable and Possible Alzheimer's Disease in Ethnically Diverse Highly Educated Individuals: An Analysis of the NACC Database. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2012, 67, 890-896.	3.6	80
119	Serum Granulocyte Colony-Stimulating Factor and Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2012, 2, 353-360.	1.3	6
120	Biomarkers of Basic Activities of Daily Living in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 31, 429-437.	2.6	13
121	Validation of a Latent Variable Representing the Dementing Process. <i>Journal of Alzheimer's Disease</i> , 2012, 30, 639-649.	2.6	45
122	Using blood markers for Alzheimer disease in clinical practice?. <i>Neurology</i> , 2012, 79, 846-847.	1.1	7
123	Implication of common and disease specific variants in CLU, CR1, and PICALM. <i>Neurobiology of Aging</i> , 2012, 33, 1846.e7-1846.e18.	3.1	36
124	Low-level arsenic exposure, AS3MT gene polymorphism and cardiovascular diseases in rural Texas counties. <i>Environmental Research</i> , 2012, 113, 52-57.	7.5	78
125	Comparison of protein concentrations in serum versus plasma from Alzheimer's patients. <i>Advances in Alzheimer's Disease</i> , 2012, 01, 51-58.	0.9	6
126	Psychological symptoms and blood pressure among rural-dwellers. <i>Journal of Health Psychology</i> , 2012, 17, 1203-1211.	2.3	2

#	ARTICLE	IF	CITATIONS
127	Characterization of Mexican Americans with Mild Cognitive Impairment and Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 33, 373-379.	2.6	90
128	The Relation between Inflammation and Neuropsychological Test Performance. International Journal of Alzheimer's Disease, 2012, 2012, 1-6.	2.0	8
129	Normative performance on the executive clock drawing task in a multi-ethnic bilingual cohort: a project FRONTIER study. International Journal of Geriatric Psychiatry, 2012, 27, 959-966.	2.7	16
130	Diagnostic Validity of Age and Education Corrections for the Mini-Mental State Examination in Older African Americans. Journal of the American Geriatrics Society, 2012, 60, 328-331.	2.6	41
131	A Blood-Based Screening Tool for Alzheimer's Disease That Spans Serum and Plasma: Findings from TARC and ADNI. PLoS ONE, 2011, 6, e28092.	2.5	126
132	Long-Term Low-Level Arsenic Exposure Is Associated with Poorer Neuropsychological Functioning: A Project FRONTIER Study. International Journal of Environmental Research and Public Health, 2011, 8, 861-874.	2.6	157
133	Executive functioning mediates the link between other neuropsychological domains and daily functioning: a Project FRONTIER study. International Psychogeriatrics, 2011, 23, 107-113.	1.0	27
134	The differential impact of depressive symptom clusters on cognition in a rural multi-ethnic cohort: a Project FRONTIER study. International Journal of Geriatric Psychiatry, 2011, 26, 199-205.	2.7	35
135	An examination of the Boston Naming Test: calculation of "estimated" 60-item score from 30- and 15-item scores in a cognitively impaired population. International Journal of Geriatric Psychiatry, 2011, 26, 351-355.	2.7	22
136	The Influence of Thyroid Function on Cognition in a Sample of Ethnically Diverse, Rural-Dwelling Women: A Project FRONTIER Study. Journal of Neuropsychiatry and Clinical Neurosciences, 2011, 23, 219-222.	1.8	8
137	Serum Brain-Derived Neurotrophic Factor Levels Are Specifically Associated with Memory Performance among Alzheimer's Disease Cases. Dementia and Geriatric Cognitive Disorders, 2011, 31, 31-36.	1.5	60
138	A Blood-Based Algorithm for the Detection of Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2011, 32, 55-62.	1.5	84
139	The RBANS Effort Index: Base Rates in Geriatric Samples. Applied Neuropsychology, 2011, 18, 11-17.	1.5	35
140	Depressive Symptom Clusters and Neuropsychological Performance in Mild Alzheimer's and Cognitively Normal Elderly. Depression Research and Treatment, 2011, 2011, 1-6.	1.3	18
141	Depression and Brain-derived Neurotrophic Factor Levels in Alzheimer's Disease. Neuroscience and Medicine, 2011, 02, 43-47.	0.2	5
142	Low-level groundwater arsenic exposure impacts cognition: a project FRONTIER study. Journal of Environmental Health, 2011, 74, 16-22.	0.5	27
143	Identifying functional impairment with scores from the repeatable battery for the assessment of neuropsychological status (RBANS). International Journal of Geriatric Psychiatry, 2010, 25, 525-530.	2.7	41
144	The Arsenic Exposure Hypothesis for Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2010, 24, 311-316.	1.3	99

#	ARTICLE	IF	CITATIONS
145	The Four-Point Scoring System for the Clock Drawing Test Does Not Differentiate between Alzheimer's Disease and Vascular Dementia. <i>Psychological Reports</i> , 2010, 106, 941-948.	1.7	10
146	Diagnostic Accuracy of the RBANS in Mild Cognitive Impairment: Limitations on Assessing Milder Impairments. <i>Archives of Clinical Neuropsychology</i> , 2010, 25, 429-441.	0.5	85
147	Diagnostic Accuracy of Percent Retention Scores on RBANS Verbal Memory Subtests for the Diagnosis of Alzheimer's Disease and Mild Cognitive Impairment. <i>Archives of Clinical Neuropsychology</i> , 2010, 25, 318-326.	0.5	19
148	The Utility of the Spatial Span in a Clinical Geriatric Population. <i>Aging, Neuropsychology, and Cognition</i> , 2010, 18, 56-63.	1.3	15
149	Validation of the New Interpretive Guidelines for the Clinical Dementia Rating Scale Sum of Boxes Score in the National Alzheimer's Coordinating Center Database. <i>Archives of Neurology</i> , 2010, 67, 746-9.	4.5	186
150	Decreased C-Reactive Protein Levels in Alzheimer Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2010, 23, 49-53.	2.3	92
151	A Serum Protein-Based Algorithm for the Detection of Alzheimer Disease. <i>Archives of Neurology</i> , 2010, 67, 1077.	4.5	210
152	On Becoming a Peer Reviewer for a Neuropsychology Journal. <i>Archives of Clinical Neuropsychology</i> , 2009, 24, 201-207.	0.5	4
153	Brain-Derived Neurotrophic Factor Levels in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2009, 17, 337-341.	2.6	89
154	Utility of the RBANS in detecting cognitive impairment associated with Alzheimer's disease: Sensitivity, specificity, and positive and negative predictive powers. <i>Archives of Clinical Neuropsychology</i> , 2008, 23, 603-612.	0.5	192
155	Detecting Dementia With the Mini-Mental State Examination in Highly Educated Individuals. <i>Archives of Neurology</i> , 2008, 65, 963-7.	4.5	486
156	Clinical Utility of Trial 1 of the Test of Memory Malingering (TOMM). <i>Applied Neuropsychology</i> , 2008, 15, 113-116.	1.5	47
157	Staging Dementia Using Clinical Dementia Rating Scale Sum of Boxes Scores. <i>Archives of Neurology</i> , 2008, 65, 1091.	4.5	607
158	The Influence of Ethnicity on Symbol Digit Modalities Test Performance: An Analysis of a Multi-Ethnic College and Hepatitis C Patient Sample. <i>Applied Neuropsychology</i> , 2007, 14, 183-188.	1.5	11
159	Test of Memory Malingering (Tomm) Trial 1 as a Screening Measure for Insufficient Effort. <i>Clinical Neuropsychologist</i> , 2007, 21, 511-521.	2.3	72
160	Examining the Test of Memory Malingering Trial 1 and Word Memory Test Immediate Recognition as Screening Tools for Insufficient Effort. <i>Assessment</i> , 2007, 14, 215-222.	3.1	68
161	Discrepancies between self-reported years of education and estimated reading level among elderly community-dwelling African-Americans: Analysis of the MOAANS data. <i>Archives of Clinical Neuropsychology</i> , 2007, 22, 327-332.	0.5	24
162	Estimating the Predictive Value of the Test of Memory Malingering: An Illustrative Example for Clinicians. <i>Clinical Neuropsychologist</i> , 2006, 20, 533-540.	2.3	60

#	ARTICLE	IF	CITATIONS
163	The Neuropsychology of Recurrent Headache. Headache, 2006, 46, 1364-1376.	3.9	36
164	Preliminary Findings on the Cross Cultural Test of Face Recognition. Applied Neuropsychology, 2006, 13, 223-229.	1.5	3
165	Neuropsychology of migraine: present status and future directions. Expert Review of Neurotherapeutics, 2005, 5, 363-370.	2.8	28
166	Hit Rates of Adequate Performance Based on the Test of Memory Malingering (TOMM) Trial 1. Applied Neuropsychology, 2005, 12, 1-4.	1.5	36
167	The Relation Between Ethnicity and Cognistat Performance in Males Seeking Substance Use Disorder Treatment. Journal of Clinical and Experimental Neuropsychology, 2005, 27, 873-885.	1.3	3
168	Discrepancies Between Self-Reported Years of Education and Estimated Reading Level: Potential Implications for Neuropsychologists. Applied Neuropsychology, 2005, 12, 5-11.	1.5	20
169	The California Verbal Learning Test-Children's Version: Relation to Factor Indices of the Wechsler Intelligence Scale for Children-Third Edition. Journal of Clinical and Experimental Neuropsychology, 2005, 27, 815-822.	1.3	5
170	The relation of self-report of mood and anxiety to CVLT-C, CVLT, and CVLT-2 in a psychiatric sample. Archives of Clinical Neuropsychology, 2005, 20, 547-553.	0.5	16
171	Reporting of Demographic Variables in Neuropsychological Research: Trends in the Current Literature. Clinical Neuropsychologist, 2004, 18, 229-233.	2.3	51
172	Attenuating Demographic Influences on Verbal Fluency and Animal Naming in a Psychiatric Sample. Applied Neuropsychology, 2004, 11, 208-212.	1.5	5
173	Performance profiles and cut-off scores on the Memory Assessment Scales*1. Archives of Clinical Neuropsychology, 2004, 19, 489-496.	0.5	14
174	A review of symptoms commonly associated with menopause: implications for clinical neuropsychologists and other health care providers. Neuropsychology Review, 2003, 13, 145-152.	4.9	30
175	Correlations Among the TOMM, Rey-15, and MMPI-2 Validity Scales in a Sample of TBI Litigants. Journal of Forensic Neuropsychology, 2003, 3, 45-53.	0.7	18
176	Utility of the Trail Making Test in the Assessment of Malingering in a Sample of Mild Traumatic Brain Injury Litigants. Clinical Neuropsychologist, 2003, 17, 69-74.	2.3	32
177	Specificity of Malingering Detection Strategies in Older Adults Using the CVLT and WCST. Clinical Neuropsychologist, 2003, 17, 255-262.	2.3	36
178	The Recognition Memory Test Examination of ethnic differences and norm validity. Archives of Clinical Neuropsychology, 2003, 18, 135-143.	0.5	7
179	APOEε4 Genotype Is Related to Brain Amyloid Among Mexican Americans in the HABS-HD Study. Frontiers in Neurology, 0, 13, .	2.4	4